TY - JOUR
TI - Impact of treatment duration and dosing on efficacy and safety in a phase 3 study of panobinostat plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma
AU - San-Miguel, JF
AU - Hungria, VTM
AU - Yoon, S-S
AU - Beksac, M
AU - Dimopoulos, MA
AU - Elghandour, A
AU - Jedrzejczak, WW
AU - Guenther, A
AU - Nakorn, TN
AU - Siritanaratkul, N
AU - others
JO - Clinical Lymphoma Myeloma and Leukemia
PY - 2015
VL - 15
TODO - null
SP - e270--e271
PB - Elsevier
SN - null
TODO - null
TODO - null
TODO - null
ER -